Carmela Ricciardelli

24PUBLICATIONS
27CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Mar 28, 2026
Correction: Khan et al. Reducing the Invasiveness of Low- and High-Grade Endometrial Cancers in Both Primary Human Cancer Biopsies and Cell Lines by the Inhibition of Aquaporin-1 Channels. <i>Cancers</i> 2023, <i>15</i>, 4507.

Sidra Khan, Noor A Lokman, Martin K Oehler

|Nov 05, 2025
Proteomics analysis of serum extracellular vesicle identifies UCHL1 as a potential therapeutic target for high grade serous ovarian cancer.

Noor A Lokman, Anne M Macpherson, Annaliese R Thompson

|Sep 13, 2025
Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer.

Riya Khetan, Noor A Lokman, Preethi Eldi

|Jun 26, 2025
Identification of Proteins Associated with Ovarian Cancer Chemotherapy Resistance Using MALDI-MSI.

Tannith M Noye, Parul Mittal, Zoe K Price

|May 27, 2024
Engineered CAR-T cells targeting the non-functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer.

Veronika Bandara, Victoria M Niktaras, Vasiliki J Willett

|Oct 10, 2023
Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer.

Zoe K Price, Noor A Lokman, Mai Sugiyama

Pageof 4

Frequent Collaborators

7 joint publications

Noor A Lokman

4 joint publications

Zoe K Price

3 joint publications

Tannith M Noye

3 joint publications

Sidra Khan